Progesterone subcutaneous - IBSA

Drug Profile

Progesterone subcutaneous - IBSA

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IBSA
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Spontaneous abortion

Most Recent Events

  • 15 Dec 2017 IBSA Institut Biochimique withdraws a phase III trial in Premenstrual syndrome in Italy prior to enrolment, before December 2017 (SC) (NCT02950948)
  • 12 Sep 2017 Chemical structure information added
  • 04 Apr 2017 Phase-III clinical trials in Spontaneous abortion in Italy (SC) (NCT02950935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top